Breuer, J. and Joppi, R. and Poggiani, C. and Dabrowska, M. and Zawodnik, A. and Nachtnebel, A. (2014): Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 45.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Falkner, E. and Wild, C. (2007): Cell salvage for minimising perioperative allogeneic blood transfers]. HTA-Newsletter 59: p. 3.

Finnish Medicines Agency (FIMEA), EUnetHTA and Norwegian Medicines Agency (NoMA), EUnetHTA (2017): Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia. EUnetHTA report. DSD: Horizon Scanning in Oncology 74.

Fischer, S. and Zechmeister-Koss, I (2012): Day Surgery. HTA- Projektbericht 64.

Fischer, S. and Zechmeister-Koss, I. (2014): Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases. HTA-Projektbericht 79.

Geiger-Gritsch, S. (2010): Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma. DSD: Horizon Scanning in Oncology 10.

Grössmann, N. (2020): Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma. Update July 2020. Oncology Fact Sheet Nr. 9.

Grössmann, N. (2020): Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML). Update July 2020. Oncology Fact Sheet Nr. 10.

Grössmann, N. (2020): Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL). Oncology Fact Sheet Nr. 15.

Grössmann, N. (2020): Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Oncology Fact Sheet Nr. 17.

Grössmann, N. (2020): Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Oncology Fact Sheet Nr. 19.

Grössmann, N. (2020): Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions. Update July 2020. Oncology Fact Sheet Nr. 1.

Grössmann, N. (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020. Oncology Fact Sheet Nr. 6.

Grössmann, N. (2020): Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL). Update July 2020. Oncology Fact Sheet Nr. 5.

Grössmann, N. (2020): Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL). Oncology Fact Sheet Nr. 14.

Grössmann, N. (2020): Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL. Oncology Fact Sheet Nr. 3.

Grössmann, N. (2016): Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM). DSD: Horizon Scanning in Oncology 63.

Grössmann, N. (2016): Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. DSD: Horizon Scanning in Oncology 62.

Grössmann, N. (2016): Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL). DSD: Horizon Scanning in Oncology 60.

Grössmann, N. and Baumann, M. (2016): Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 57.

Götz, G. and Hawlik, K. (2020): Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. Update 2020. Decision Support Document 106/ Update 2020.

Hawlik, K. and Wild, C. (2017): Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS. Decision Support Document 106.

Hintringer, K. (2012): Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma. DSD: Horizon Scanning in Oncology 29.

Hintringer, K. (2012): Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL). DSD: Horizon Scanning in Oncology 26.

Hintringer, K. (2012): Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy. DSD: Horizon Scanning in Oncology 25.

Hintringer, K. (2012): Quality Appraisal of Written Consumer Health Information for Patients with Chronic Myeloid Leukaemia (CML) . HTA-Projektbericht 52.

Hintringer, K. (2011): Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 17.

Hintringer, K. (2011): Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 15.

Hintringer, K. (2010): Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma. DSD: Horizon Scanning in Oncology 08.

Langer, T. (2006): [Stem cell transplantation for acute leukemia]. HTA-Newsletter 52: pp. 2-3.

McGahan , L (2018): Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia. DSD: Horizon Scanning in Oncology 85.

McGahan, L. (2019): Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs). DSD: Horizon Scanning in Oncology 89.

Nachtnebel, A. (2013): Pomalidomide (Pomalidomide Celgene/Pomalyst®) for the ≥ 3rd-line therapy of patients with relapsed and refractory multiple myeloma. DSD: Horizon Scanning in Oncology 39.

Nachtnebel, A. (2011): Rituximab (Rituxan®/MabThera®)for the first- and second-line treatment of chronic lymphocytic leukaemia - 1st Update 2011. DSD: Horizon Scanning in Oncology 04 / Update 2011.

Nachtnebel, A. (2009): Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes. DSD: Horizon Scanning in Oncology 01.

Nachtnebel, A. (2009): Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma. DSD: Horizon Scanning in Oncology 05.

Nachtnebel, A. and Breuer, J. (2014): Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 47.

Nachtnebel, A. and Maran , P.R. and Alberti, C. and Garbaty , T. and Czeczot , J. (2012): Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion. DSD: Horizon Scanning in Oncology 28.

Poggiani, C. and Nachtnebel, A. (2012): Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma. DSD: Horizon Scanning in Oncology 33.

Rosian, K. and Stanak, M. (2018): Lymphovenous anastomoses in patients with primary and secondary lymphoedema. Decision Support Document 110.

Rothschedl, E and Nachtnebel, A (2015): Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy . DSD: Horizon Scanning in Oncology 52.

Rothschedl, E. (2018): Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma. DSD: Horizon Scanning in Oncology 81.

Rothschedl, E. (2018): Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL). DSD: Horizon Scanning in Oncology 79.

Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.

Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.

Warmuth, M. (2009): Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 04.

Warmuth, M. and Mad, P. and Wild, C. (2009): Haemocomplettan® P alone or in combination with Fibrogammin® P in acquired hypofibrinogenemia. HTA-Projektbericht 039.

Warmuth, M. and Nachtnebel, A. (2012): Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes. Decision Support Document 53.

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. HTA-Newsletter 58: p. 4.

Wild, C. (2005): [Immunoglobulin in neonates and preterm infants]. HTA-Newsletter 41: pp. 2-3.

Wild, C. (2005): . HTA-Newsletter 40: p. 4.

Wild, C. (2005): [Autologous blood donation]. HTA-Newsletter 38: p. 2.

Wild, C. (2004): [Rituximab (MabThera®) as treatment for non-Hodgkin's lymphoma]. HTA-Newsletter 32: p. 3.

Wild, C. (2004): [Sentinel node biopsy (SNB) in breast cancer]. HTA-Newsletter 24: pp. 2-3.

Wild, C. (2003): [Tumour vaccination]. HTA-Newsletter 19: p. 4.

Wild, C. (2001): [Stem cell research, quo vadis? Editorial]. HTA-Newsletter 03: pp. 1-2.

Wild, C. (2001): [Erythropoietin for anaemic tumour patients]. HTA-Newsletter 01: p. 2.

Wild, C. (2001): [Stem cells: Quo vadis?]. ITA-Newsletter September 2001: pp. 8-9.

Wild, C. (2000): [EPO for cancer related anaemia]. ITA-Newsletter April 2000: p. 5.

Wild, C. and Jonas, S. (2000): [EPO in cancer anaemia]. ITA-Newsletter September 2000: pp. 2-3.

Wild, C. and Jonas, S. (2000): [Erythropoietin in tumour anaemia. An assessment]. ITA-Projektbericht 15.

Wild, C. and Mathis, S. and Guba, B. and Gartlehner, G. (2008): [Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review]. Decision Support Document 12.

Wild, C. (2007): [FDA: Safety warning on erythropoietin]. ÖKZ: Österreichische Krankenhauszeitung 48 (07).

Wild, C. (2003): [Erythropoietin: The impact of HTA]. ÖKZ: Österreichische Krankenhauszeitung 44 (12): pp. 9-10.

Wild, C. (2003): [Erythropoietin: The impact of HTA] . Mitteilungen der Sanitätsverwaltung 104 (9): p. 23.

Wild, C. (2002): Erythropoietin in tumor anemia - for whom is effective?. International Journal of Cancer 13 (Supplement): p. 70.

Wild, C. (2001): [Stem cell research, quo vadis?]. ORF ON Science.

Wild, C. (2001): [Assessing medical interventions: Erythropoietin in tumour anaemia]. TA-Datenbank-Nachrichten (01, Sonderheft): pp. 51-55.

Wild, C. (2000): [Erythropoietin in patients with fatigue syndrome]. forum dr. Med. (13): pp. 4-5.

Wild, C. and Jonas, S. (2001): [Health policy decisions between rationing and rationalisation as demonstrated by the example of erythropoietin in tumour anaemia]. Das Gesundheitswesen 63 (2): pp. 221-225.

Wild, C. and Jonas, S. (2000): [Erythropoietin (EPO) in tumour anaemia]. Newsletter der Österreichischen Gesellschaft für Public Health (4): pp. 1-2.

Winkler, R. and Rosian, K. (2016): Supply Mandates. HTA-Projektbericht 88.

Zechmeister, I. and Mathis, S. and Guba, B. and Gartlehner, G. (2008): [LDL apheresis. Systematic review]. Decision Support Document 07.